Please assess the completion status of the following clinical trial:

Trial Title: A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. 18 years or older~2. Clinical diagnosis of XLH~3. TmP/GFR \< 2.0 mg/dL~4. GFR ≥60 mL/min~5. Corrected Ca \<10.8 mg/dL~6. A willingness to utilize adequate contraception and not become pregnant\[or to have their partner(s) become pregnant\] during the study~7. Additional inclusion criteria apply~Main Exclusion Criteria:~1. Have any sign of active infectious disease or have had an infection requiring treatment with antibiotics within 3-weeks of Screening~2. History of known immunodeficiency~3. Pregnant or lactating females subjects or female planning to be become pregnant during the study~4. Receipt of a live (attenuated) vaccine (except for influenza vaccines) within 3-months of Screening, and/or during the study~5. Use of pharmacologic vitamin D metabolite or its analog, phosphate, calcimimetics, and ingestion of aluminum hydroxide antacids within 10-days prior to Screening and/or dosing~6. Use of any supplement containing phosphate, calcium and/or vitamin D within 10-days prior to Screening and/or dosing~7. Condition which could present a concern for either the subject's safety or difficulty with data interpretation~8. Additional exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KRN23 (Type: EXPERIMENTAL): Escalating doses of KRN23 (0.05, 0.10, 0.30 and 0.60 mg/kg) will be administered SC every 28 days (up to 4 doses)

Based on this trial design, predict the completion outcome and termination type (if applicable).